AstraZeneca PLCAZN announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone. Symbicort is presently marketed for the treatment ...
AstraZenecaAZN announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol. Symbicort is a combination formulation containing budesonide, an inhaled ...
MISSISSAUGA, ON, Sept. 30, 2019 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort ® Turbuhaler ® (budesonide ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback